Kiri Industries Limited

Basis. Consolidated figures for FY23–FY25 and 9M-FY26 are from the March 2026 IP. FY26 full-year figures are derived as 9M-FY26 plus Q4-FY26 from the Q1-FY27 Release and reconcile to the reported FY26 totals (revenue INR 8,396.5 Mn; PBT INR 55,942.5 Mn; PAT before associates INR 53,793 Mn; consolidated net profit including associates INR 55,669 Mn). FY22 figures are as reported in FY22 releases and by aggregators and are on a different consolidation basis.

Consolidated income statement

Notes:

1. FY22 revenue (INR 1,496.9 Cr) is from Anand Rathi and reconciles to the quarterly FY22 releases (Q1 292.78 + Q2 357.87 + Q3 429.41 + Q4 about 417 Cr). FY22 EBITDA (INR 123.3 Cr), PBT (INR 68.3 Cr) and PAT before associates (INR 52.9 Cr) are from Anand Rathi. FY22 net profit including associates (INR 3,890 Mn) and EPS are from TipRanks. FY22 associate income and tax are derived residuals. The FY22 row is not on the same consolidation basis as FY23 onward.

2. FY26 diluted EPS of INR 900.91 is from share.market; quarterly diluted EPS sums to about INR 905.

3. FY26 EBITDA includes a non-cash year-end adjustment of about INR 1,137 Mn (FilingReader, 30 May 2026). Management's adjusted FY26 consolidated EBITDA was INR 127 Cr (ScanX, Jun 2026).

4. Gross profit is not reported in this form by the company. The standalone material margin is the closest proxy.

5. No dividend has been paid for about 10 years (Q1-FY27 call).

Consolidated margins and growth (%)

Revenue CAGR on the company's restated basis was about 7.9% a year from FY23 to FY26 (INR 6,679 Mn to INR 8,397 Mn). The FY22–FY26 CAGR on as-reported figures (about -13.5%) is not meaningful because the consolidation basis changed. FY22 revenue growth uses FY21 revenue of INR 957.0 Cr (Anand Rathi).

Standalone income statement

FY26 standalone EBITDA, depreciation and finance cost are derived as 9M-FY26 (March 2026 IP) plus Q4-FY26 (Q1-FY27 Release). FY26 standalone PAT of INR 5,580.9 Cr (558,090.20 lakh) is as reported (FilingReader, 30 May 2026). Management cited FY26 standalone "operational EBITDA" of INR 79 Cr after adding back about INR 114 Cr of non-cash year-end adjustments (FilingReader, 3 Jun 2026). FY22 standalone: net loss of about INR 9.3 Cr versus INR 37 Cr loss in FY21 (Q4-FY22 call transcript).

Consolidated quarterly trajectory

Q2/Q3 other income and Q2 finance cost were not separately verified and are shown as 0 (not disclosed in the sources reviewed). Q2 and Q3 EBITDA and PAT are derived from H1 and 9M totals and reconcile with reported net profit (Q2 INR 19.65 Cr per Capital Market; Q3 about INR 5,022 Cr per MarketsMojo).

Consolidated balance sheet

Source: March 2026 IP. Net worth was INR 26,513 Mn at FY23. No goodwill is reported.

FY26 year-end (partly derived):

• Gross debt was INR 406.2 Mn and net debt to equity was -0.16x, i.e. net cash (Q4-FY26 and Q1-FY27 fact sheets).

• Aggregator book value per share ranged from INR 988 to 1,063, implying consolidated net worth of roughly INR 64,000 to 69,000 Mn.

• Applying -0.16x to about INR 64,000 Mn gives implied net cash of about INR 10,000 Mn at 31 March 2026.

• The DyStar investment was derecognised on exit. Contingent liabilities are about INR 1,494 Cr (Screener).

Cash flow

Known facts:

• Consolidated net cash flow was about INR +341 Cr in FY26 (Screener).

• USD 689.03 Mn (about INR 58,540 to 58,620 Mn) was received on 31 Dec 2025.

• Approximate uses (Trade Brains summary of management commentary): FY26 tax of about INR 2,100 to 2,200 Mn; Claronex debt (about INR 12,000 Mn at H1-FY26) repaid by March 2026; IACL equity rising from INR 1,036 Cr (Sep 2024) to about INR 1,400 Cr by August 2026; IAFL INR 70 Cr; working capital and contingencies.

• Dividends paid: nil throughout FY22–FY26. Buybacks: none.

• Copper and fertilizer project capex (cash) has been rising sharply since October 2025. A project-level capex figure for FY26 is not publicly disclosed.

Key ratios

How these were calculated:

• ROE uses average equity. FY26 ROE uses an approximate year-end equity of INR 64,000 Mn; Simply Wall St reports 114.97%.

• ROA uses average total assets.

• FY23 debt to equity, FY23 current ratio and FY23/FY26 asset turnover are not computable from the sources reviewed and are shown as 0.

• Interest coverage uses EBITDA excluding other income; it is negative or not meaningful throughout.

• ROIC is not meaningful: operating income was negative, and invested capital was dominated by a non-operating investment until December 2025.

• Net debt/EBITDA is not meaningful because EBITDA was negative.

Standalone cash conversion cycle (revenue-based approximation):

• FY24: receivable days about 39, inventory days about 71, payable days about 206, giving a CCC of about -96 days. Payables were swollen by stretched creditors during the litigation years.

• FY25: about 53, 85 and 102 days respectively, giving a CCC of about +36 days, as the company paid down trade payables (INR 3,581 Mn to INR 1,831 Mn) after the preferential issue.

Commentary on trends, inflections and drivers

1. The operating business is chronically loss-making at the EBITDA line. Since FY23 the standalone chemicals business has posted negative EBITDA before other income (FY23 -18%, FY24 -10%, FY25 -7% of revenue). Causes include Chinese H-Acid and Vinyl Sulphone dumping, low utilisation (about 60%), high fixed costs at sub-scale, and DyStar litigation costs charged through operating expenses. FY26 looked worse (-26%) largely because of non-cash year-end adjustments (about INR 114 Cr) and Q3-Q4 one-offs. Management's adjusted FY26 consolidated EBITDA was positive at INR 127 Cr.

2. Q1-FY27 is the first clean operating inflection. Consolidated core EBITDA turned positive at INR 15.9 Cr (5.1% margin) versus -INR 16.3 Cr a year earlier. Standalone material margin expanded to 31.9% from 23.5% as H-Acid and VS prices rose faster than inputs. Revenue grew 55% YoY, almost entirely from price rather than volume.

3. Profit has historically come from associates. In FY23–FY25, associate income (INR 2,575 to 3,732 Mn a year, mainly DyStar) exceeded total consolidated net profit. With DyStar gone, recurring associate income falls to Lonsen Kiri only (about INR 580 Mn in FY26; about INR 207 Mn in Q1-FY27, or about INR 800 Mn annualised).

4. Finance costs have collapsed. Finance cost rose from INR 63 Mn (FY23) to INR 1,953 Mn (FY26) because of the high-cost Claronex judgment-based funding (about USD 130 Mn) used to start the copper project early. It fell to INR 14 Mn in Q1-FY27 after repayment. Expect it to rise again, partly capitalised during construction, as INR 4,000 to 5,000 Cr of project debt is drawn in FY27–FY28.

5. The balance sheet has been transformed. It has moved from a stretched, payables-funded structure in FY24 (current ratio 0.43x) to net cash at FY26. Net worth roughly doubled to about INR 64,000 to 69,000 Mn. A large portion is already committed to equity funding of IACL and IAFL.

6. Earnings quality is low. FY26 and Q1-FY27 net profit are dominated by exceptional and treasury items: INR 58,813 Mn exceptional income, and Q1-FY27 other income of INR 2,859 Mn including reversal of a prior-quarter non-cash charge. The headline trailing P/E (about 0.5 to 0.6x) is therefore meaningless.

Management guidance (latest)

• Core chemicals: over 20% growth in FY27, standalone revenue above INR 1,000 Cr, utilisation rising to 70–75%, and continued pass-through of input costs.

• Copper: tube plant in Q1-FY28, rod plant in Q2-FY28, refinery between Q4-FY28 and Q3-FY29. First revenue around May–June 2027. The majority of copper revenue is targeted in Q4 of FY2029–30.

• Funding: project capex of about INR 12,000 Cr; about INR 1,400 Cr of equity deployed; INR 4,000–5,000 Cr of debt; financial closure "in the next few months".

• No dividend.

Consensus growth expectations

No published consensus estimates are available.

Bull case

1. Deep discount to cash and book. The market cap (about INR 3,504 Cr) is about 0.5 times book, and FY26 net cash of about INR 1,000 Cr plus about INR 1,400 Cr already invested in project equity represent a large share of the market value. Core chemicals and the 40% Lonsen Kiri stake (about INR 80 Cr a year in associate profit at the Q1-FY27 run-rate) are effectively valued near zero.

2. Cyclical upturn in intermediates. Q1-FY27 material margin of 31.9% and positive core EBITDA show operating leverage. With about 40% spare capacity, standalone revenue above INR 1,000 Cr at 8–12% EBITDA margins is plausible if China's enforcement persists.

3. Strategic value of the copper and fertilizer complex. India's roughly 1 Mt refined-copper gap and roughly 4.5 Mt DAP import dependence, plus INR 3,000–3,500 Cr of state incentives and the acid-to-fertilizer integration, could support the claimed ~25% IRR. That would create a business many times today's revenue base, with promoters (41.7% and rising) aligned by subscribing at INR 475.

Bear case

1. Execution and funding risk on a project about 3.5 times the market cap. Financial closure is incomplete, capex guidance has drifted, the FY28 revenue target has been withdrawn, and a third party (Celsius) is lobbying Kiri's financiers. Cost overruns or delays could force heavy dilution or leverage.

2. Weak smelting economics. With TC/RC at zero, a custom smelter without captive mines depends on by-product credits and fertilizer margins exposed to subsidy policy. Incumbents (Hindalco, Adani) have scale and logistics advantages, and Kiri secures only about two-thirds of the concentrate it needs.

3. Governance and earnings quality. No dividend despite a INR 5,800+ Cr windfall; repeated promoter warrant issues; a combined Chair/MD; heavy non-cash and treasury items in reported profit; and new overseas legal entanglements in the Philippines. These justify a persistent conglomerate and governance discount, and FPIs have reduced holdings from 25.9% to 16.7%.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict

Kiri Industries has completed one of the more remarkable minority-shareholder recoveries in Asian corporate history. It turned a disputed 37.57% stake in DyStar into USD 689 million of cash after a decade of litigation, and the balance sheet moved from fragile to net-cash almost overnight.

The market's response has been instructive. The stock fell more than half from its December 2025 peak to March 2026, and still trades at about half of book value. That reflects scepticism about what management chose to do next: retain every rupee, pay no dividend, and commit roughly INR 12,000 to 13,000 crore to a greenfield copper smelter and fertilizer complex in which the company has no operating history.

The underlying chemicals business offers modest support. After four years of negative EBITDA before other income, Q1-FY27 showed a genuine, price-led turnaround: 55% revenue growth, a 31.9% material margin and positive core EBITDA. Its durability depends on Chinese supply discipline. Lonsen Kiri remains a solid earner.

The equity is now essentially an option on project execution. The strategic logic is coherent: India is structurally short of refined copper and phosphates, acid-to-fertilizer integration hedges zero TC/RCs, and experienced project leaders and TCE add credibility. Against that sit an incomplete financial closure, drifting capex and timeline guidance, a withdrawn FY28 revenue target, a two-thirds concentrate cover, and new legal friction in the Philippines that has spilled toward Kiri's financiers.

Our assessment is speculative positive on value, with governance and execution caveats. The roughly 0.5x price-to-book discount appears to over-penalise a cash-rich company with an improving core. Re-rating, however, requires three proofs: financial closure on reasonable terms, on-time commissioning of the copper tube and rod plants in 2027, and a credible capital-return framework.

---

All figures are from company filings, investor presentations and cited third-party sources as of 7 October 2026. Derived figures are labelled as such.